Ocular Tissue Engineering Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Ophthalmic Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Orbit. 2020 Apr;39(2):107-111. doi: 10.1080/01676830.2019.1631358. Epub 2019 Jul 8.
: To evaluate the effect of intra-lesional injection of Trichloroacetic acid (TCA) 10% in patients with conjunctival inclusion cysts.: This prospective case series study included all patients with conjunctival inclusion cyst who were referred to our referral center from August 2016 to August 2018. All patients received TCA 10% injection into the conjunctival cyst, and outcomes of the intervention were evaluated at least 6 months later.: Ten patients with mean age of 24 ± 17.6 (range 6-65) years including three children received TCA 10% injection into the conjunctival cyst. We included 6 anophthalmic and 4 ophthalmic cases. All patients were treated successfully and no recurrence of the lesion was observed in any case. Mean follow up duration was 18.1 ± 8.3 (range 6-28) months.: Intra-lesional injection of TCA 10% is a safe, simple, and effective treatment in patients with conjunctival inclusion cysts including ophthalmic cases and anophthalmic cases, both in adults and in children. This concentration may avoid ocular surface complications.
: 评估 10%三氯乙酸（TCA）腔内注射治疗结膜包涵囊肿的效果。: 本前瞻性病例系列研究纳入了 2016 年 8 月至 2018 年 8 月期间因结膜包涵囊肿就诊于我院的所有患者。所有患者均接受结膜囊肿内 10%TCA 注射治疗，至少在 6 个月后评估干预结果。: 10 例患者，平均年龄 24 ± 17.6 岁（6-65 岁），包括 3 例儿童。我们纳入了 6 例无眼窝和 4 例眼窝病例。所有患者均成功治疗，无任何病例出现病变复发。平均随访时间为 18.1 ± 8.3 个月（6-28 个月）。: 结膜包涵囊肿患者（包括眼窝和无眼窝病例），成人和儿童均适用 10%TCA 腔内注射治疗，操作简单、安全、有效。这种浓度可能避免眼表并发症。
